Randomized trial shows radium-223 improves overall survival in metastatic prostate cancer, indicating its potential benefit.
In this study, which was terminated for efficacy at the prespecified interim analysis, radium-223 improved overall survival. (Funded by Algeta and Bayer HealthCare Pharmaceuticals; ALSYMPCA ClinicalTrials.gov number, NCT00699751.).
No takes yet. Share an insight, caveat, or question.
Parker et al. (2013) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: